Henlius Biotech (2696 HK) – Promising Ph2 Data of Innovative Assets
⬆ $Shanghai Henlius Biotech (02696)$ - In the study, a total of 53 patients were randomized to Group A (HLX22 25mg/kg + Hanquyou + chemo), Group B (HLX22 15mg/kg + Hanquyou + chemo) and Group C (Hanquyou + chemo).
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/henlius-biotech-2696-hk-promising-ph2-data-of-innovative-assets?utm_source=tiger_community
By CMB International, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cmb-international?utm_source=tiger_community
On Shanghai Henlius Biotech (02696):- https://www.smartkarma.com/entities/shanghai-henlius-biotech-inc?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
